DB:BTPC

Stock Analysis Report

Executive Summary

Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops drugs for the treatment of neurodegenerative, inflammatory, and cancer diseases in Sweden.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Active Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BTPC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.0%

BTPC

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

-20.0%

BTPC

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: BTPC underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: BTPC underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

BTPCIndustryMarket
7 Day1.0%-4.3%-4.7%
30 Day3.9%-6.7%-4.0%
90 Day19.1%0.4%-1.4%
1 Year-20.0%-20.0%5.8%5.5%11.7%8.3%
3 Year-76.5%-82.3%40.9%39.4%11.4%1.6%
5 Year-89.1%-91.9%10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is Active Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Active Biotech undervalued compared to its fair value and its price relative to the market?

8.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BTPC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BTPC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BTPC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BTPC is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BTPC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BTPC is overvalued based on its PB Ratio (8.2x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Active Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Active Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Active Biotech performed over the past 5 years?

37.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BTPC is currently unprofitable.

Growing Profit Margin: BTPC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BTPC is unprofitable, but has reduced losses over the past 5 years at a rate of 37.9% per year.

Accelerating Growth: Unable to compare BTPC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BTPC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: BTPC has a negative Return on Equity (-63.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Active Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: BTPC's short term assets (SEK63.8M) exceed its short term liabilities (SEK11.2M).

Long Term Liabilities: BTPC's short term assets (SEK63.8M) exceed its long term liabilities (SEK2.0M).


Debt to Equity History and Analysis

Debt Level: BTPC is debt free.

Reducing Debt: BTPC has no debt compared to 5 years ago when its debt to equity ratio was 55.7%.


Balance Sheet

Inventory Level: BTPC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BTPC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BTPC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BTPC has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 36% each year.


Next Steps

Dividend

What is Active Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BTPC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BTPC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BTPC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BTPC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BTPC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

Helén Tuvesson (57yo)

2.6yrs

Tenure

kr2,617,000

Compensation

Ms. Helén Tuvesson is President and Chief Executive Officer of Active Biotech AB ("Active Biotech"). She has a PhD in medical science from Lund University. She has extensive experience in drug development  ...


CEO Compensation Analysis

Compensation vs Market: Helén's total compensation ($USD268.88K) is below average for companies of similar size in the German market ($USD414.81K).

Compensation vs Earnings: Helén's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Peter Thelin
Independent Director8.8yrskr125.00k1.96% SEK822.0k
Uli Hacksell
Director0.8yrsno datano data
Michael Shalmi
Chairman of the Board0.8yrsno datano data
Peter Sjöstrand
Independent Director20.1yrskr125.00k0.027% SEK11.2k

4.8yrs

Average Tenure

66yo

Average Age

Experienced Board: BTPC's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.


Top Shareholders

Company Information

Active Biotech AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Active Biotech AB (publ)
  • Ticker: BTPC
  • Exchange: DB
  • Founded: 1982
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr442.971m
  • Listing Market Cap: kr41.891m
  • Shares outstanding: 145.24m
  • Website: https://www.activebiotech.com

Number of Employees


Location

  • Active Biotech AB (publ)
  • Scheelevägen 22
  • Lund
  • 223 63
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACTIOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKJun 1995
0GQULSE (London Stock Exchange)YesOrdinary SharesGBSEKJun 1995
BTPCDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1995
ACTIsBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKJun 1995

Biography

Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops drugs for the treatment of neurodegenerative, inflammatory, and cancer diseases in Sweden. The company is involved in developing ANYARA, a tumor targeting superantigen to kill tumor cell; Tasquinimod, an oral immunomodulatory compound for the treatment of multiple myeloma, a form of blood cancer; and SILC, an S100A9 inhibition by low molecular weight compounds for the treatment of cancer. It is also developing Laquinimod, an oral immunomodulatory drug that has completed Phase II clinical trial for Huntington’s disease; and Paquinimod, an oral immunomodulatory compound that has completed Phase I clinical trial for the treatment of systemic lupus erythematosus and systemic sclerosis. The company has a partnership agreement with NeoTX Therapeutics Ltd. for the development of naptumumab. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 21:37
End of Day Share Price2020/02/25 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.